Novel bivalent ligands for D2/D3 dopamine receptors: Significant cooperative gain in D2 affinity and potency

ACS Medicinal Chemistry Letters

Volumn 3, Issue 12, 2012, Pages 991-996

  Gogoi, Sanjib ^a,c   Biswas, Swati ^a   Modi, Gyan ^a   Antonio, Tamara ^b   Reith, Maarten E A ^b   Dutta, Aloke K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c CSIR NEIST   (India)

Author keywords

affinity; bivalent ligands; cooperative gain; D2 D3 dopamine receptors; potency; synergism

Indexed keywords

5 HYDROXY 2 (DIPROPYLAMINO)TETRALIN; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; HOMODIMER; LIGAND; ROPINIROLE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CELL STRAIN HEK293; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR UPREGULATION;

EID: 84871255186     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml3002117     Document Type: Article

References (27)

1. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat Rev. Drug Discovery 2006, 5, 993-996
2. Lagerstrom, M. C.; Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discovery 2008, 7, 339-357
3. Park, P. S.; Filipek, S.; Wells, J. W.; Palczewski, K. Oligomerization of G protein-coupled receptors: Past, present, and future Biochemistry 2004, 43, 15643-15656
4. Portoghese, P. S. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J. Med. Chem. 2001, 44, 2259-2269
5. Hebert, T. E.; Moffett, S.; Morello, J. P.; Loisel, T. P.; Bichet, D. G.; Barret, C.; Bouvier, M. A peptide derived from a beta2-Adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation J. Biol. Chem. 1996, 271, 16384-16392
6. Hern, J. A.; Baig, A. H.; Mashanov, G. I.; Birdsall, B.; Corriea, J. E.; Lazareno, S.; Molloy, J. E.; Birdsall, N. J. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2693-2698
7. Lee, S. P.; O'Dowd, B. F.; Ng, G. Y.; Varghese, G.; Akil, H.; Mansour, A.; Nguyen, T.; George, S. R. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell Mol. Pharmacol. 2000, 58, 120-128
8. Nimchinsky, E. A.; Hof, P. R.; Janssen, W. G.; Morrison, J. H.; Schmauss, C. Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells J. Biol. Chem. 1997, 272, 29229-29237
9. Zawarynski, P.; Tallerico, T.; Seeman, P.; Lee, S. P.; O'Dowd, B. F.; George, S. R. Dopamine D2 receptor dimers in human and rat brain FEBS Lett. 1998, 441, 383-386
10. Rashid, A. J.; So, C. H.; Kong, M. M.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B. F.; George, S. R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 654-659
11. Portoghese, P. S.; Larson, D. L.; Sayre, L. M.; Yim, C. B.; Ronsisvalle, G.; Tam, S. W.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors J. Med. Chem. 1986, 29, 1855-1861
12. Zhang, Y.; Gilliam, A.; Maitra, R.; Damaj, M. I.; Tajuba, J. M.; Seltzman, H. H.; Thomas, B. F. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor J. Med. Chem. 2010, 53, 7048-7060
13. Bhushan, R. G.; Sharma, S. K.; Xie, Z.; Daniels, D. J.; Portoghese, P. S. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers J. Med. Chem. 2004, 47, 2969-2972
14. Portoghese, P. S. Bivalent ligands and the message-Address concept in the design of selective opioid receptor antagonists Trends Pharmacol. Sci. 1989, 10, 230-235
15. Kramer, R. H.; Karpen, J. W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers Nature 1998, 395, 710-713
16. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641-651
17. Kuhhorn, J.; Hubner, H.; Gmeiner, P. Bivalent dopamine D2 receptor ligands: synthesis and binding properties J. Med. Chem. 2011, 54, 4896-4903
18. Kuhhorn, J.; Gotz, A.; Hubner, H.; Thompson, D.; Whistler, J.; Gmeiner, P. Development of a bivalent dopamine D(2) receptor agonist J. Med. Chem. 2011, 54, 7911-7919
19. McRobb, F. M.; Crosby, I. T.; Yuriev, E.; Lane, J. R.; Capuano, B. Homobivalent ligands of the atypical antipsychotic clozapine: Design, synthesis, and pharmacological evaluation J. Med. Chem. 2012, 55, 1622-1634
20. Huber, D.; Lober, S.; Hubner, H.; Gmeiner, P. Bivalent molecular probes for dopamine D2-like receptors Bioorg. Med. Chem. 2012, 20, 455-466
21. Birnkammer, T.; Spickenreither, A.; Brunskole, I.; Lopuch, M.; Kagermeier, N.; Bernhardt, G.; Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H(2) receptor agonists J. Med. Chem. 2012, 55, 1147-1160
22. Cox, B. A.; Henningsen, R. A.; Spanoyannis, A.; Neve, R. L.; Neve, K. A. Contributions of Conserved Serine Residues to the Interactions of Ligands with Dopamine D2 Receptors J. Neurochem. 1992, 59, 627-635
23. Mansour, A.; Meng, F.; Meador-Woodruff, J. H.; Taylor, L. P.; Civelli, O.; Akil, H. Site-directed mutagenesis of the human dopamine D2 receptor Eur. J. Pharmacol. 1992, 227, 205-214
24. Kortagere, S.; Cheng, S. Y.; Antonio, T.; Zhen, J.; Reith, M. E.; Dutta, A. K. Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies Biochem. Pharmacol. 2011, 81, 157-163
25. Biswas, S.; Zhang, S.; Fernandez, F.; Ghosh, B.; Zhen, J.; Kuzhikandathil, E.; Reith, M. E.; Dutta, A. K. Further structure-Activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}- 5,6,7,8-tetrahydronaphthalen-2-o l analogues: Identification of a high-Affinity D3-preferring agonist with potent in vivo activity with long duration of action J. Med. Chem. 2008, 51, 101-117
26. Newman-Tancredi, A.; Cussac, D.; Audinot, V.; Pasteau, V.; Gavaudan, S.; Millan, M. J. G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5′-O-(3-[35S] thio)- triphosphate binding and antibody study Mol. Pharmacol. 1999, 55, 564-574
27. Ghosh, B.; Antonio, T.; Reith, M. E. A.; Dutta, A. K. Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl) piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson's Disease J. Med. Chem. 2010, 53, 2114-2125